Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
COSMIC project: consensus on the objectives of the metabolic syndrome in clinic.
Juan Pedro-Botet,Juan F. Ascaso,Juan F. Ascaso,Vivencio Barrios,Vivencio Barrios,Alejandro de la Sierra,Javier Escalada,Jesús Millán,José M. Mostaza,Pablo Perez-Martinez,Pablo Perez-Martinez,Xavier Pintó,Xavier Pintó,Jordi Salas-Salvadó,Pedro Valdivielso +14 more
TL;DR: In this article, the authors developed a consensus document to establish recommendations on therapeutic goals that facilitate their homogenization in clinical decision-making, where professionals from different scientific societies who are involved in the management of the different MetS components reviewed the available scientific evidence focused basically on therapeutic aspects of MetS and developed consensus document.
Journal ArticleDOI
Cardiovascular disease risk reduction in rural China: A clustered randomized controlled trial in Zhejiang
Xiaolin Wei,Guanyang Zou,Weiwei Gong,Jia Yin,Yunxian Yu,John Walley,Zhitong Zhang,Rebecca King,Kun Chen,Marc K. C. Chong,Benny Zee,Su Liu,Jin-Ling Tang,Sian M. Griffiths,Min Yu +14 more
TL;DR: Whether the systematic CVD risk reduction package results in reduced CVD events among patients at risk of CVD compared with usual care, and whether the package is cost-effective and suitable for routine implementation and scale-up are determined.
Journal ArticleDOI
Antithrombotic therapy in diabetes: Which, when, and for how long?
Ramzi A. Ajjan,Noppadol Kietsiriroje,Noppadol Kietsiriroje,Lina Badimon,Lina Badimon,Gemma Vilahur,Diana A. Gorog,Diana A. Gorog,Dominick J. Angiolillo,David Russell,David Russell,Bianca Rocca,Robert F. Storey +12 more
TL;DR: In this article, the authors provide an up-to-date guide for antithrombotic management of individuals with diabetes mellitus and highlight gaps in knowledge that represent areas for future research aiming to improve clinical outcome in this high-risk population.
Journal ArticleDOI
The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease.
TL;DR: This review will provide a comprehensive overview of available antiplatelet agents used to treat coronary artery cardiovascular disease and the risks of bleeding with each agent will be considered.
Journal ArticleDOI
Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves.
Ankur Pandya,Stephen Sy,Sylvia Cho,Sartaj Alam,Milton C. Weinstein,Thomas A. Gaziano,Thomas A. Gaziano,Thomas A. Gaziano +7 more
TL;DR: The simulation model performed well in matching to observed nationally representative longitudinal mortality data, and ROC curve analysis, which has been traditionally used for risk prediction models, can be used to assess discrimination for disease simulation models.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.